Table 1.
Correlation of pretreatment LMR with clinicopathologic characteristics of patients with advanced cervical carcinoma (n = 424)
| Characteristic | No. of patients (%) | Pretreatment LMR level | p value | HPV DNA status | p value | ||
|---|---|---|---|---|---|---|---|
| High value (n = 260) | Low value (n = 164) | HR-positive (n = 390) | Non-HR (n = 34) | ||||
| Age, years | |||||||
| ≤46 | 205 (48.35 %) | 133 | 72 | 0.146 | 190 | 15 | 0.607 |
| >46 | 219 (51.65 %) | 127 | 92 | 200 | 19 | ||
| HPV DNA | |||||||
| Positive | 390 (91.98 %) | 246 | 144 | 0.012 | – | – | – |
| Negative | 34 (8.02 %) | 14 | 20 | – | – | ||
| Lymph node status classification | |||||||
| Node-negative | 277 (65.33 %) | 212 | 65 | 0.001 | 252 | 25 | 0.295 |
| Node-positive | 147 (34.67 %) | 48 | 99 | 138 | 9 | ||
| FIGO classification | |||||||
| IIA | 86 (20.28 %) | 41 | 45 | 0.0 22 | 81 | 5 | 0.803 |
| IIB | 84 (19. 81 %) | 48 | 36 | 78 | 6 | ||
| IIIA | 92 (21.70 %) | 63 | 29 | 83 | 9 | ||
| IIIB | 90 (21.23 %) | 61 | 29 | 81 | 9 | ||
| IVA | 72 (16.98 %) | 47 | 25 | 67 | 5 | ||
| Pathological type | |||||||
| SCC | 305 (71.93 %) | 194 | 111 | 0.337 | 288 | 17 | 0.016 |
| ADC | 31 (7.31 %) | 19 | 12 | 25 | 6 | ||
| ASC | 33 (7.78 %) | 19 | 14 | 29 | 4 | ||
| UDC | 55 (12.97 %) | 28 | 27 | 48 | 7 | ||
| Treatment modality | |||||||
| IC + RT | 143 (33.73 %) | 83 | 60 | 0.607 | 132 | 11 | 0.984 |
| CCRT | 147 (34.67 %) | 92 | 55 | 135 | 12 | ||
| IC + CCRT | 134 (31.60 %) | 85 | 49 | 123 | 11 | ||
LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; SCC squamous cell carcinoma; Ag antigen; FIGO International Federation of Gynecology and Obstetrics; ADC adenocarcinoma; ASC adenosquamous carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; HR high risk